Scholarlink

<p>Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma with a poor prognosis and short survival rates. It is classified as a large B-cell lymphoma subtype, but carries a plasmacytic immunophenotype. Therefore, PBL has pathogenetic overlaps with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) and plasma cell neoplasms (PCNs). Although recent studies have characterized important genetic abnormalities in PBL, the precise molecular mechanisms driving its pathogenesis remain elusive. In this study, we analyzed 607 inflammatory genes in 10 PBL, 11 DLBCL NOS/high-grade B-cell lymphoma (DLBCL NOS/HGBCL), and 11 PCN samples to uncover the PBL immunoregulatory landscape and to identify promising therapeutic target candidates. Several differentially expressed genes were observed, including <i>STAT4</i>, <i>STAT5A</i>, and <i>MAPK14</i>, with enriched pathways such as <i>JAK</i>-<i>STAT</i>, nuclear factor-kappa B (<i>NF-κB</i>), and complement signaling in the PBL group. Notably, <i>CR2</i> was underexpressed in PBL compared to DLBCL NOS/HGBCL and PCNs, suggesting a restricted Wp latency stage of Epstein–Barr virus (EBV), which may contribute to immune evasion. Functional analyses identified key immune pathways, including cytokine–receptor interactions, Toll-like receptor signaling, and neutrophil extracellular trap formation, with protein–protein interaction networks, emphasizing complement activation and <i>JAK-STAT</i> signaling pathways. In conclusion, oral PBL exhibits a complex inflammatory gene expression profile, and key signaling pathways, particularly <i>JAK-STAT</i>, <i>NF-κB</i>, and complement activation, are enriched in this tumor compared to DLBCL NOS/HGBCL and PCNs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inflammatory gene expression profile of oral plasmablastic lymphoma

  • 期刊论文

  • 发表日期：

    2025年9月10日

查看全文
  • Roberta Rayra Martins-Chaves,
  • Marina Gonçalves Diniz,
  • Fernanda Faria Rocha,
  • Cinthia Veronica Bardález López de Cáceres,
  • Pablo Agustin Vargas,
  • Bruno Augusto Benevenuto de Andrade,
  • Aline Araújo Sampaio,
  • Nicolau Conte Neto,
  • Hélder Antônio Rebelo Pontes,
  • Ricardo Alves Mesquita,
  • Ciro Dantas Soares,
  • Guilherme Rossi Assis de Mendonça,
  • Ricardo Santiago Gomez,
  • Felipe Paiva Fonseca

摘要

Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma with a poor prognosis and short survival rates. It is classified as a large B-cell lymphoma subtype, but carries a plasmacytic immunophenotype. Therefore, PBL has pathogenetic overlaps with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) and plasma cell neoplasms (PCNs). Although recent studies have characterized important genetic abnormalities in PBL, the precise molecular mechanisms driving its pathogenesis remain elusive. In this study, we analyzed 607 inflammatory genes in 10 PBL, 11 DLBCL NOS/high-grade B-cell lymphoma (DLBCL NOS/HGBCL), and 11 PCN samples to uncover the PBL immunoregulatory landscape and to identify promising therapeutic target candidates. Several differentially expressed genes were observed, including STAT4, STAT5A, and MAPK14, with enriched pathways such as JAK-STAT, nuclear factor-kappa B (NF-κB), and complement signaling in the PBL group. Notably, CR2 was underexpressed in PBL compared to DLBCL NOS/HGBCL and PCNs, suggesting a restricted Wp latency stage of Epstein–Barr virus (EBV), which may contribute to immune evasion. Functional analyses identified key immune pathways, including cytokine–receptor interactions, Toll-like receptor signaling, and neutrophil extracellular trap formation, with protein–protein interaction networks, emphasizing complement activation and JAK-STAT signaling pathways. In conclusion, oral PBL exhibits a complex inflammatory gene expression profile, and key signaling pathways, particularly JAK-STAT, NF-κB, and complement activation, are enriched in this tumor compared to DLBCL NOS/HGBCL and PCNs.